Overview
Portfolio
More
Hongying Capital
Focus on China’s real economy with a “value creation, price realization” philosophy, investing across healthcare, consumer, media, environmental, new energy, and manufacturing sectors.
Portfolio
9+
Employees
250+
Founded
2003
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
China
Sources
Hongying Capital
Focus on China’s real economy with a “value creation, price realization” philosophy, investing across healthcare, consumer, media, environmental, new energy, and manufacturing sectors.
Portfolio
9+
Employees
250+
Founded
2003
AUM
N/A
Stages
No stages listed
Industries
No industries listedGeographic scope
China
Sources
Showing 9 of 9 matched portfolio companies
AgiBot develops and manufactures humanoid robots and embodied intelligence systems designed for various applications, including interactive services and flexible manufacturing. Their technology enhances productivity by automating tasks in diverse environments, addressing labor shortages and operational inefficiencies.
CharacterX provides a decentralized AI companion network that enables users to create, mint, and trade AI characters as NFTs, facilitating personalized interactions and content generation. The platform addresses the lack of ownership and governance in AI character creation by transforming these digital assets into tradable items on a Web3 infrastructure.
H Company develops AI models, including VLMs and LLMs, to automate web processes and enhance decision-making for businesses. Their technology increases worker productivity by streamlining repetitive tasks and improving operational efficiency.
Funding: $220.0M
Rough estimate of the amount of funding raised
Funding: $220.0M
Rough estimate of the amount of funding raised
The startup operates a molecular imaging platform that utilizes non-invasive radiopharmaceutical imaging technology to detect early-stage colorectal, esophageal, and lung adenocarcinoma. This technology enables healthcare providers to make precise diagnoses and tailor cancer treatment plans, improving patient outcomes and care efficiency.
10+
200+Approximate amount of employees
Funding: $2.5M
Rough estimate of the amount of funding raised
Funding: $2.5M
Rough estimate of the amount of funding raised
TAKE MI HOME is an online platform that connects customers with certified beauty and wellness professionals who provide services such as massages, physiotherapy, and personal training directly in their homes. By offering a streamlined booking process and exclusive treatments from Terme di Saturnia, the platform addresses the need for convenient, high-quality self-care solutions tailored to individual preferences.
Funding: $50.0K
Rough estimate of the amount of funding raised
Funding: $50.0K
Rough estimate of the amount of funding raised
This startup offers an online platform that empowers women and LGBTQ artists to launch and manage NFT initiatives, utilizing decentralized finance tools to enhance visibility and access to resources. By fostering a community-driven ecosystem, the platform addresses the lack of equitable opportunities in the crypto space for underrepresented creators.
Funding: $4.5M
Rough estimate of the amount of funding raised
Funding: $4.5M
Rough estimate of the amount of funding raised
一手App is a digital wholesale platform that aggregates garment suppliers from major Chinese markets and offers daily, buyer‑curated collections online. Retailers can purchase single pieces at near‑wholesale prices through limited‑time group‑buy events, with real‑time product visuals, partial free‑shipping and return options that lower inventory risk and eliminate the need to travel to physical markets.
Shargetech develops and manufactures gallium nitride (GaN) chargers that provide faster charging times and improved energy efficiency for consumer electronics. By utilizing GaN technology, these chargers reduce heat generation and size, addressing the demand for compact and high-performance charging solutions.
The startup develops TCR gene therapy solutions that provide personalized immunotherapy for cancer patients by engineering T-cell receptors to target specific tumor antigens. This approach enhances treatment efficacy and minimizes side effects compared to traditional therapies.